Annual CFO
$3.54 B
-$592.60 M-14.35%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual cash flow from operations is currently $3.54 billion, with the most recent change of -$592.60 million (-14.35%) on 31 December 2023. During the last 3 years, it has risen by +$283.80 million (+8.72%). VRTX annual CFO is now -14.35% below its all-time high of $4.13 billion, reached on 31 December 2022.VRTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$1.37 B
+$5.12 B+136.49%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly cash flow from operations is currently $1.37 billion, with the most recent change of +$5.12 billion (+136.49%) on 30 September 2024. Over the past year, it has increased by +$101.40 million (+7.99%). VRTX quarterly CFO is now at all-time high.VRTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$842.60 M
+$101.40 M+10.74%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM cash flow from operations is currently -$842.60 million, with the most recent change of +$101.40 million (+10.74%) on 30 September 2024. Over the past year, it has dropped by -$5.22 billion (-119.23%). VRTX TTM CFO is now -119.23% below its all-time high of $4.38 billion, reached on 30 September 2023.VRTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.3% | +8.0% | -119.2% |
| 3 y3 years | +8.7% | +47.7% | -139.4% |
| 5 y5 years | +178.5% | +309.1% | -158.6% |
VRTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -14.3% | +33.8% | at high | +136.5% | -119.2% | +10.7% |
| 5 y | 5 years | -14.3% | +178.5% | at high | +136.5% | -119.2% | +10.7% |
| alltime | all time | -14.3% | +656.7% | at high | +136.5% | -119.2% | +10.7% |
Vertex Pharmaceuticals Incorporated Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.37 B(-136.5%) | -$842.60 M(-10.7%) |
| June 2024 | - | -$3.75 B(-387.3%) | -$944.00 M(-123.9%) |
| Mar 2024 | - | $1.31 B(+456.9%) | $3.94 B(+11.5%) |
| Dec 2023 | $3.54 B(-14.3%) | $234.60 M(-81.5%) | $3.54 B(-19.3%) |
| Sept 2023 | - | $1.27 B(+11.8%) | $4.38 B(+7.7%) |
| June 2023 | - | $1.13 B(+26.1%) | $4.07 B(-0.1%) |
| Mar 2023 | - | $899.90 M(-16.6%) | $4.07 B(-1.4%) |
| Dec 2022 | $4.13 B(+56.2%) | $1.08 B(+12.9%) | $4.13 B(+2.1%) |
| Sept 2022 | - | $955.50 M(-16.2%) | $4.05 B(+0.7%) |
| June 2022 | - | $1.14 B(+19.2%) | $4.02 B(+50.0%) |
| Mar 2022 | - | $956.20 M(-3.9%) | $2.68 B(+1.3%) |
| Dec 2021 | $2.64 B(-18.7%) | $995.00 M(+7.3%) | $2.64 B(+23.5%) |
| Sept 2021 | - | $927.20 M(-564.3%) | $2.14 B(+0.9%) |
| June 2021 | - | -$199.70 M(-121.7%) | $2.12 B(-36.9%) |
| Mar 2021 | - | $921.00 M(+87.4%) | $3.36 B(+3.2%) |
| Dec 2020 | $3.25 B(+107.3%) | $491.53 M(-45.9%) | $3.25 B(+1.4%) |
| Sept 2020 | - | $907.75 M(-12.6%) | $3.21 B(+21.7%) |
| June 2020 | - | $1.04 B(+27.3%) | $2.63 B(+27.9%) |
| Mar 2020 | - | $815.70 M(+82.9%) | $2.06 B(+31.3%) |
| Dec 2019 | $1.57 B(+23.5%) | $445.98 M(+33.2%) | $1.57 B(+9.1%) |
| Sept 2019 | - | $334.79 M(-27.8%) | $1.44 B(-3.1%) |
| June 2019 | - | $463.75 M(+42.8%) | $1.48 B(+10.6%) |
| Mar 2019 | - | $324.78 M(+3.2%) | $1.34 B(+5.7%) |
| Dec 2018 | $1.27 B(+50.3%) | $314.58 M(-17.5%) | $1.27 B(+7.4%) |
| Sept 2018 | - | $381.35 M(+18.5%) | $1.18 B(+21.7%) |
| June 2018 | - | $321.70 M(+27.3%) | $971.96 M(+16.8%) |
| Mar 2018 | - | $252.66 M(+11.1%) | $831.91 M(-1.5%) |
| Dec 2017 | $844.94 M(+257.9%) | $227.51 M(+33.8%) | $844.94 M(+10.9%) |
| Sept 2017 | - | $170.09 M(-6.4%) | $762.15 M(+15.9%) |
| June 2017 | - | $181.65 M(-31.6%) | $657.73 M(+27.2%) |
| Mar 2017 | - | $265.69 M(+83.6%) | $516.93 M(+118.9%) |
| Dec 2016 | $236.10 M(-164.6%) | $144.72 M(+120.4%) | $236.10 M(+95.9%) |
| Sept 2016 | - | $65.66 M(+60.7%) | $120.52 M(-1772.3%) |
| June 2016 | - | $40.86 M(-369.9%) | -$7.21 M(-95.4%) |
| Mar 2016 | - | -$15.14 M(-151.9%) | -$158.33 M(-56.7%) |
| Dec 2015 | -$365.43 M(-36.2%) | $29.14 M(-146.9%) | -$365.43 M(-36.6%) |
| Sept 2015 | - | -$62.07 M(-43.7%) | -$576.36 M(-4.2%) |
| June 2015 | - | -$110.27 M(-50.4%) | -$601.93 M(-2.8%) |
| Mar 2015 | - | -$222.24 M(+22.3%) | -$619.59 M(+8.1%) |
| Dec 2014 | -$573.11 M(+844.7%) | -$181.78 M(+107.4%) | -$573.11 M(+54.2%) |
| Sept 2014 | - | -$87.65 M(-31.5%) | -$371.57 M(+24.8%) |
| June 2014 | - | -$127.92 M(-27.2%) | -$297.64 M(+74.4%) |
| Mar 2014 | - | -$175.76 M(-989.5%) | -$170.65 M(+181.3%) |
| Dec 2013 | -$60.67 M(-122.7%) | $19.76 M(-244.0%) | -$60.67 M(+52.2%) |
| Sept 2013 | - | -$13.72 M(+1380.0%) | -$39.87 M(-149.9%) |
| June 2013 | - | -$927.00 K(-98.6%) | $79.81 M(-59.9%) |
| Mar 2013 | - | -$65.78 M(-262.2%) | $199.15 M(-25.6%) |
| Dec 2012 | $267.84 M(+86.3%) | $40.56 M(-61.7%) | $267.84 M(-63.4%) |
| Sept 2012 | - | $105.96 M(-10.5%) | $730.95 M(+9.4%) |
| June 2012 | - | $118.41 M(+3960.5%) | $667.88 M(+100.4%) |
| Mar 2012 | - | $2.92 M(-99.4%) | $333.28 M(+131.9%) |
| Dec 2011 | $143.74 M(-122.6%) | $503.66 M(+1074.2%) | $143.74 M(-127.3%) |
| Sept 2011 | - | $42.90 M(-119.8%) | -$526.03 M(-28.2%) |
| June 2011 | - | -$216.19 M(+15.8%) | -$732.92 M(+17.2%) |
| Mar 2011 | - | -$186.63 M(+12.4%) | -$625.61 M(-1.5%) |
| Dec 2010 | -$635.44 M(+48.6%) | -$166.10 M(+1.3%) | -$635.44 M(+11.2%) |
| Sept 2010 | - | -$163.99 M(+50.6%) | -$571.67 M(+33.2%) |
| June 2010 | - | -$108.89 M(-44.6%) | -$429.31 M(-2.1%) |
| Mar 2010 | - | -$196.46 M(+92.0%) | -$438.49 M(+2.5%) |
| Dec 2009 | -$427.59 M(+88.8%) | -$102.33 M(+373.0%) | -$427.59 M(+1.2%) |
| Sept 2009 | - | -$21.64 M(-81.7%) | -$422.48 M(-20.0%) |
| June 2009 | - | -$118.06 M(-36.4%) | -$528.33 M(+72.4%) |
| Mar 2009 | - | -$185.56 M(+90.9%) | -$306.51 M(+35.3%) |
| Dec 2008 | -$226.48 M | -$97.22 M(-23.7%) | -$226.48 M(+24.5%) |
| Sept 2008 | - | -$127.48 M(-222.9%) | -$181.95 M(+54.1%) |
| June 2008 | - | $103.76 M(-198.3%) | -$118.11 M(-59.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$105.53 M(+100.3%) | -$290.20 M(+14.9%) |
| Dec 2007 | -$252.48 M(+1023.4%) | -$52.69 M(-17.2%) | -$252.48 M(+23.7%) |
| Sept 2007 | - | -$63.64 M(-6.9%) | -$204.07 M(+424.2%) |
| June 2007 | - | -$68.33 M(+0.8%) | -$38.93 M(+31.6%) |
| Mar 2007 | - | -$67.81 M(+1481.7%) | -$29.57 M(+31.6%) |
| Dec 2006 | -$22.48 M(-86.9%) | -$4.29 M(-104.2%) | -$22.48 M(-10.8%) |
| Sept 2006 | - | $101.50 M(-272.1%) | -$25.19 M(-86.2%) |
| June 2006 | - | -$58.98 M(-2.8%) | -$183.00 M(+2.9%) |
| Mar 2006 | - | -$60.71 M(+766.9%) | -$177.93 M(+3.4%) |
| Dec 2005 | -$172.05 M(+21.0%) | -$7.00 M(-87.6%) | -$172.05 M(-8.8%) |
| Sept 2005 | - | -$56.31 M(+4.5%) | -$188.69 M(+7.2%) |
| June 2005 | - | -$53.91 M(-1.7%) | -$176.06 M(+21.3%) |
| Mar 2005 | - | -$54.83 M(+131.9%) | -$145.12 M(+2.1%) |
| Dec 2004 | -$142.16 M(-15.2%) | -$23.64 M(-45.9%) | -$142.16 M(-3.4%) |
| Sept 2004 | - | -$43.67 M(+90.1%) | -$147.22 M(-3.2%) |
| June 2004 | - | -$22.97 M(-55.7%) | -$152.08 M(-10.2%) |
| Mar 2004 | - | -$51.87 M(+80.7%) | -$169.42 M(+1.1%) |
| Dec 2003 | -$167.62 M(+110.7%) | -$28.70 M(-40.9%) | -$167.62 M(+10.0%) |
| Sept 2003 | - | -$48.53 M(+20.4%) | -$152.40 M(+24.8%) |
| June 2003 | - | -$40.32 M(-19.5%) | -$122.15 M(+23.0%) |
| Mar 2003 | - | -$50.07 M(+271.6%) | -$99.33 M(+24.9%) |
| Dec 2002 | -$79.54 M(+1028.7%) | -$13.48 M(-26.3%) | -$79.54 M(+234.1%) |
| Sept 2002 | - | -$18.29 M(+4.5%) | -$23.81 M(-45.3%) |
| June 2002 | - | -$17.50 M(-42.2%) | -$43.55 M(+51.2%) |
| Mar 2002 | - | -$30.28 M(-171.7%) | -$28.80 M(+308.7%) |
| Dec 2001 | -$7.05 M(-44.5%) | $42.26 M(-211.1%) | -$7.05 M(-88.1%) |
| Sept 2001 | - | -$38.03 M(+1284.5%) | -$59.19 M(+88.5%) |
| June 2001 | - | -$2.75 M(-67.8%) | -$31.41 M(+452.6%) |
| Mar 2001 | - | -$8.52 M(-13.8%) | -$5.68 M(-55.3%) |
| Dec 2000 | -$12.71 M(-60.0%) | -$9.89 M(-3.5%) | -$12.71 M(-299.2%) |
| Sept 2000 | - | -$10.25 M(-144.6%) | $6.38 M(+108.3%) |
| June 2000 | - | $22.98 M(-247.8%) | $3.06 M(-109.4%) |
| Mar 2000 | - | -$15.55 M(-269.0%) | -$32.45 M(+2.0%) |
| Dec 1999 | -$31.80 M(+2.3%) | $9.20 M(-167.8%) | -$31.80 M(-38.6%) |
| Sept 1999 | - | -$13.56 M(+8.2%) | -$51.80 M(+39.1%) |
| June 1999 | - | -$12.54 M(-15.9%) | -$37.23 M(+10.2%) |
| Mar 1999 | - | -$14.90 M(+38.0%) | -$33.80 M(+8.7%) |
| Dec 1998 | -$31.10 M(+230.9%) | -$10.80 M(-1180.0%) | -$31.10 M(+30.7%) |
| Sept 1998 | - | $1.00 M(-111.0%) | -$23.80 M(-13.8%) |
| June 1998 | - | -$9.10 M(-25.4%) | -$27.60 M(+46.0%) |
| Mar 1998 | - | -$12.20 M(+248.6%) | -$18.90 M(+101.1%) |
| Dec 1997 | -$9.40 M(-76.7%) | -$3.50 M(+25.0%) | -$9.40 M(+6.8%) |
| Sept 1997 | - | -$2.80 M(+600.0%) | -$8.80 M(-31.8%) |
| June 1997 | - | -$400.00 K(-85.2%) | -$12.90 M(-62.8%) |
| Mar 1997 | - | -$2.70 M(-6.9%) | -$34.70 M(-13.9%) |
| Dec 1996 | -$40.30 M(+151.9%) | -$2.90 M(-58.0%) | -$40.30 M(+8.6%) |
| Sept 1996 | - | -$6.90 M(-68.9%) | -$37.10 M(+7.2%) |
| June 1996 | - | -$22.20 M(+167.5%) | -$34.60 M(+79.3%) |
| Mar 1996 | - | -$8.30 M(-2866.7%) | -$19.30 M(+20.6%) |
| Dec 1995 | -$16.00 M(+8.8%) | $300.00 K(-106.8%) | -$16.00 M(-26.3%) |
| Sept 1995 | - | -$4.40 M(-36.2%) | -$21.70 M(+9.0%) |
| June 1995 | - | -$6.90 M(+38.0%) | -$19.90 M(+22.8%) |
| Mar 1995 | - | -$5.00 M(-7.4%) | -$16.20 M(+10.2%) |
| Dec 1994 | -$14.70 M(-270.9%) | -$5.40 M(+107.7%) | -$14.70 M(-1570.0%) |
| Sept 1994 | - | -$2.60 M(-18.8%) | $1.00 M(-73.0%) |
| June 1994 | - | -$3.20 M(-8.6%) | $3.70 M(-47.1%) |
| Mar 1994 | - | -$3.50 M(-134.0%) | $7.00 M(-18.6%) |
| Dec 1993 | $8.60 M(-262.3%) | $10.30 M(>+9900.0%) | $8.60 M(-368.8%) |
| Sept 1993 | - | $100.00 K(0.0%) | -$3.20 M(-31.9%) |
| June 1993 | - | $100.00 K(-105.3%) | -$4.70 M(-19.0%) |
| Mar 1993 | - | -$1.90 M(+26.7%) | -$5.80 M(+9.4%) |
| Dec 1992 | -$5.30 M(+112.0%) | -$1.50 M(+7.1%) | -$5.30 M(+39.5%) |
| Sept 1992 | - | -$1.40 M(+40.0%) | -$3.80 M(+58.3%) |
| June 1992 | - | -$1.00 M(-28.6%) | -$2.40 M(+71.4%) |
| Mar 1992 | - | -$1.40 M | -$1.40 M |
| Dec 1991 | -$2.50 M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual cash flow from operations?
- What is the all time high annual CFO for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual CFO year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly cash flow from operations?
- What is the all time high quarterly CFO for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly CFO year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM cash flow from operations?
- What is the all time high TTM CFO for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM CFO year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual cash flow from operations?
The current annual CFO of VRTX is $3.54 B
What is the all time high annual CFO for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual cash flow from operations is $4.13 B
What is Vertex Pharmaceuticals Incorporated annual CFO year-on-year change?
Over the past year, VRTX annual cash flow from operations has changed by -$592.60 M (-14.35%)
What is Vertex Pharmaceuticals Incorporated quarterly cash flow from operations?
The current quarterly CFO of VRTX is $1.37 B
What is the all time high quarterly CFO for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly cash flow from operations is $1.37 B
What is Vertex Pharmaceuticals Incorporated quarterly CFO year-on-year change?
Over the past year, VRTX quarterly cash flow from operations has changed by +$101.40 M (+7.99%)
What is Vertex Pharmaceuticals Incorporated TTM cash flow from operations?
The current TTM CFO of VRTX is -$842.60 M
What is the all time high TTM CFO for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM cash flow from operations is $4.38 B
What is Vertex Pharmaceuticals Incorporated TTM CFO year-on-year change?
Over the past year, VRTX TTM cash flow from operations has changed by -$5.22 B (-119.23%)